Table 2.
Demographic and oncological variables of patients who underwent at least a second neurological examination (n = 42 patients).
| Patient characteristics | N. (%) |
|---|---|
| Gender | |
| Male | 18 (42.9%) |
| Female | 24 (57.1%) |
| AGE (mean, SD) (median, IQR) | 52 (±12) (52, 45–62) |
| Histology | |
| Lung (NSCLC, SCLC) | 21 (50%) |
| Breast | 13 (31%) |
| Melanoma | 4 (9.5%) |
| Bladder | 2 (4.8%) |
| Other | 2 (4.8%) |
| Brain metastases site | |
| Frontal | 9 (21.4%) |
| Temporal | 4 (9.5%) |
| Parietal | 7 (16.7%) |
| Occipital | 4 (9.5%) |
| Multilobular | 18 (42.9%) |
| Side of brain metastases | |
| Left | 13 (31.0%) |
| Right | 12 (28.6%) |
| Both | 17 (40.5%) |
| Number of lesions (median, range) | 1 (1–8) |
| Type of sistemic therapy | |
| None | 7 (16.7%) |
| Biological | 10 (23.8%) |
| Chemotherapy | 14 (33.3%) |
| Immunotherapy | 4 (9.5%) |
| Chemotherapy + biological | 7 (16.7%) |
| Brain metastases surgery | 18 (42.9%) |
| Radiotherapy for brain metastases | 37 (88.1%) |
| Whole brain | 20 (54.1%) |
| Intensity modulated | 0 |
| Conformational | 1 (2.7%) |
| Stereotactic | 10 (27.0%) |
| Radiosurgery | 6 (16.2%) |
| Mutation/genic expression | |
| None | 27 (64.2%) |
| Egfr | 4 (9.5%) |
| Her2 | 6 (14.3%) |
| Ckit | 1 (2.4%) |
| Braf | 2 (4.8%) |
| Alk | 2 (4.8%) |
SD, standard deviation; IQR, interquartile range; EGFR, estimated glomerular filtration rate; HER2, human epidermal growth factor receptor 2; CKIT, tyrosine protein kinase inhibitors; BRAF, murine sarcoma viral oncogene homolog B1; and ALK, anaplastic lymphoma kinase.